N
Nuclera
Making biology accessible by providing researchers a desktop bioprinter capable to produce genes and proteins in one day
About Nuclera
Nuclera is a biotechnology company specializing in on-demand gene to protein synthesis, enabling scientists to create, build, and engineer biology directly in their own laboratories. The company serves researchers and scientists in the field of synthetic biology, providing high-quality genes and proteins with a focus on speed, flexibility, and accuracy. Nuclera operates in the synthetic biology market, leveraging a biologically inspired platform that allows for the rapid construction of genes, often within a day. The business model revolves around selling its proprietary technology and related services to laboratories and research institutions, generating revenue through the sale of its synthesis platform and consumables. By making gene and protein writing accessible and customizable, Nuclera aims to revolutionize the way biological research is conducted.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Histon, United Kingdom
- Employees
- 130
- Open positions
- 5
- Dealroom signal
- 81.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Synthetic Biology, Genome Engineering, Tech for Biotech and Pharma, Biotech and Pharma, BIA Techbio UK, Techbio, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2026 | $12M | $48M | British Business Bank · Jonathan Milner · Elevage Medical Technologies · GK Goh Financial Services | ↗ |
| GROWTH EQUITY VCOther financing | Oct 2025 | $68M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Nuclera is 7.5K monthly website visits, down 21.9% over the last three months. Nuclera's team declined 3.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
M&G- RPRT Partners
Amadeus Capital Partners
British Business Bank
Yuantai Technology Industrial
Future Planet Capital- GHG. K. Goh Holdings
Verve Ventures
Jonathan Milner
Series B and later6 investors entered at this stage
Elevage Medical Technologies
Cambridge Innovation Capital
Patient Square Capital
British Patient Capital
Michael McCreary- GSGK Goh Financial Services
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nuclera on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nuclera’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.